2025-06-16-Bernstein-洁定集团（GETIB）_洁定公司_首次覆盖评级为与市场表现一致-成为行业翘楚仍需努力_100页_13mb

Summary for Getinge (GETIB.SS)

1. Rating and Price Target: The stock is rated Market-Perform with a 12-month price target of SEK228 (23% upside), reflecting a Market-Perform rating. The conclusion is that while further margin improvement is needed, the company’s strength lies in its Acute Care Therapies (ACT) division. The stock is currently trading at a 24.8% discount to its 5-year average P/E and a 33.5% discount to the sector index.

2. Company Overview:

   • Getinge is a Swedish medtech company with three main divisions: Acute Care Therapies (52% revenue, 64% adj. EBITDA), Surgical Workflows (35% revenue, 24% adj. EBITDA), and Life Sciences (13% revenue, 12% adj. EBITDA).
   • A key acquisition, Paragonix, enhances growth in ACT and offers diversification. Recent FDA letters triggered concerns but sales in critical care are stabilizing.

3. Financials:

   • Revenue growth is projected at 5.5% CAGR (2024-2029), driven by ACT, especially through consumables.
   • Adj. EBITDA margins increased by around 2000 bp in 2024-2029E, with ROIC showing gradual traction toward the WACC.
   • Net debt/EBITDA at 1.9x (target 2.5x) provides flexibility for strategic investments.

4. Valuation:

   • A 20-year DCF valuation (WACC 9.7%, terminal growth 3%) supports a SEK228 PT.
   • Comparative analysis using EV/EBITDA and peer data confirms the view that Getinge is undervalued relative to its 5-year average and the sector.

5. Key Risks:

   • US tariffs (SEK5 billion impact) and regulatory issues (e.g., FDA letters) are significant risks.
   • Continued margin pressure in Surgical Workflows and Life Sciences needs cost optimization.

Market-Perform recommendation with SEK228 PT